India to United States: Rituximab Export Trade Route
India has recorded 19 verified shipments of Rituximab exported to United States, representing a combined trade value of $312.7K USD. This corridor is served by 5 active Indian exporters, with an average shipment value of $16.5K USD. The leading Indian exporter is DR REDDYS LABORATORIES LIMITED, which accounts for 65% of total export value with 5 shipments worth $202.3K USD. On the buying side, UPS WAREHOUSE is the largest importer in United States with $297.9K USD in purchases. The top 3 suppliers — DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD, VEA IMPEX (I) PRIVATE LIMITED — together control of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Rituximab corridor is one of India's established pharmaceutical export routes, with 19 shipments documented worth a combined $312.7K USD. The route is dominated by DR REDDYS LABORATORIES LIMITED, which alone accounts for roughly 65% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.
Across 5 active suppliers, the average shipment value stands at $16.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (60%) and air (40%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during April-June, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 25.2%, placing it at rank #2 among India's top rituximab export destinations globally.
On the import side, key buyers of Indian rituximab in United States include UPS WAREHOUSE, TO THE ORDER OF INVOICE RAISED TO, TO THE ORDER OF INVOICE RAISED TO- and 7 others. UPS WAREHOUSE is the single largest importer with 6 shipments valued at $297.9K USD.
